Mercieca-Bebber, R., Barnes, E. H., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., Barbour, A. P., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D.. BioMed Central (BMC); 2022. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.